Evidence map›Paper›PMID 24732711›Full record

ArticlePloS one2014

Cellular processing of myocilin.

Ye Qiu, Xiang Shen, Rajalekshmy Shyam, Beatrice Y J T Yue, Hongyu Ying

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Protein misfolding and mitochondrial dysfunction in glaucoma.Frontiers in cell and developmental biology · 2025
    Review
  6. Article
  7. Article
  8. Modeling complex age-related eye disease.Progress in retinal and eye research · 2024
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ye QiuDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States of America.
Xiang ShenDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States of America.
Rajalekshmy ShyamDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States of America.
Beatrice Y J T YueDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States of America.
Hongyu YingDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States of America.
University of Illinois Chicago · US

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI AAKALU, VINAY · 1985 to 2025
$14.8M
BIOLOGY OF TRABECULAR MESHWORK IN HEALTH &DISEASER01EY005628 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI YUE, BEATRICE Y.J.T. · 1985 to 2009
$3.4M
Cellular Processing of Optineurin, the Product of a Glaucoma GeneR01EY018828 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI YUE, BEATRICE Y.J.T. · 2009 to 2012
$1.7M
NEI NIH HHS EY001792NEI NIH HHS EY005628NEI NIH HHS EY018828NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY005628NEI NIH HHS R01 EY018828
6 · The paper itself

Abstract

backgroundMyocilin (MYOC) is a gene linked directly to juvenile- and adult-onset open angle glaucoma. Mutations including Pro370Leu (P370L) and Gln368stop (Q368X) have been identified in patients. In the present study, we investigated the processing of myocilin in human trabecular meshwork (TM) cells as well as in inducible, stable RGC5 cell lines. METHODOLOGY/PRINCIPAL

findingsThe turnover and photoactivation experiments revealed that the endogenous myocilin in human trabecular meshwork (TM) cells was a short-lived protein. It was found that the endogenous myocilin level in TM cells was increased by treatment of lysosomal and proteasomal inhibitors, but not by autophagic inhibitor. Multiple bands immunoreactive to anti-ubiquitin were seen in the myocilin pull down, indicating that myocilin was ubiquitinated. In inducible cell lines, the turnover rate of overexpressed wild-type and mutant P370L and Q368X myocilin-GFP fusion proteins was much prolonged. The proteasome function was compromised and autophagy was induced. A decreased PSMB5 level and an increased level of autophagic marker, LC3, were demonstrated. CONCLUSIONS/SIGNIFICANCE: The current study provided evidence that in normal homeostatic situation, the turnover of endogenous myocilin involves ubiquitin-proteasome and lysosomal pathways. When myocilin was upregulated or mutated, the ubiquitin-proteasome function is compromised and autophagy is induced. Knowledge of the degradation pathways acting on myocilin can help in design of novel therapeutic strategies for myocilin-related glaucoma.

Indexed as

Protein Processing, Post-TranslationalAdultAutophagybeta CateninCell LineCytoskeletal ProteinsEye ProteinsGlycoproteinsGreen Fluorescent ProteinsHumansLightMicrotubule-Associated ProteinsMutationMyocilinProteasome Endopeptidase ComplexRecombinant Fusion Proteinsbeta CateninCytoskeletal ProteinsEye ProteinsGlycoproteinsGreen Fluorescent ProteinsMAP1LC3A protein, humanMicrotubule-Associated ProteinsMyocilinProteasome Endopeptidase ComplexPSMB5 protein, humanRecombinant Fusion Proteins

Identifiers

PMID24732711
PMCPMC3986080
OpenAlexW1988100478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.